- Home
- ADAP vs NRXS Comparison
ADAP vs NRXS Comparison
Compare ADAP & NRXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADAP
- NRXS
- Stock Information
- Founded
- ADAP 2008
- NRXS 2011
- Country
- ADAP United Kingdom
- NRXS United States
- Employees
- ADAP N/A
- NRXS N/A
- Industry
- ADAP Biotechnology: Pharmaceutical Preparations
- NRXS
- Sector
- ADAP Health Care
- NRXS
- Exchange
- ADAP Nasdaq
- NRXS Nasdaq
- Market Cap
- ADAP 21.3M
- NRXS 25.0M
- IPO Year
- ADAP 2015
- NRXS 2023
- Fundamental
- Price
- ADAP $0.06
- NRXS $2.43
- Analyst Decision
- ADAP Hold
- NRXS Strong Buy
- Analyst Count
- ADAP 6
- NRXS 1
- Target Price
- ADAP $1.02
- NRXS $7.00
- AVG Volume (30 Days)
- ADAP 62.3M
- NRXS 37.5K
- Earning Date
- ADAP 11-12-2025
- NRXS 11-11-2025
- Dividend Yield
- ADAP N/A
- NRXS N/A
- EPS Growth
- ADAP N/A
- NRXS N/A
- EPS
- ADAP N/A
- NRXS N/A
- Revenue
- ADAP $65,084,999.00
- NRXS $3,217,531.00
- Revenue This Year
- ADAP N/A
- NRXS $62.14
- Revenue Next Year
- ADAP $52.35
- NRXS $131.87
- P/E Ratio
- ADAP N/A
- NRXS N/A
- Revenue Growth
- ADAP N/A
- NRXS 41.93
- 52 Week Low
- ADAP $0.04
- NRXS $1.33
- 52 Week High
- ADAP $1.17
- NRXS $6.20
- Technical
- Relative Strength Index (RSI)
- ADAP 38.42
- NRXS 46.82
- Support Level
- ADAP $0.06
- NRXS $2.40
- Resistance Level
- ADAP $0.07
- NRXS $2.48
- Average True Range (ATR)
- ADAP 0.01
- NRXS 0.11
- MACD
- ADAP 0.01
- NRXS -0.00
- Stochastic Oscillator
- ADAP 53.33
- NRXS 24.24
About ADAP Adaptimmune Therapeutics plc
Adaptimmune Therapeutics PLC is a commercial-stage biopharmaceutical company working to redefine the treatment of solid tumor cancers with cell therapies. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70, and others for multiple cancer types.
About NRXS Neuraxis Inc.
Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).